WARD-CGM: Continuous Glucose Monitoring
Study design
Sample size
80 participants grouped as:
n=20 (Type 1 diabetes)
n=20 (Type 2 diabetes treated with insulin)
n=20 (Type 2 diabetes treated with oral anti hyperglycemic drugs and/or GLP-1 analogs)
n=20 (No diabetes)
Study sites
Bispebjerg Hospital and Rigshospitalet
Inclusion criteria
Adult patients undergoing acute or elective major abdominal surgery, major orthopedic surgery or major arterial vascular surgery.
Study Procedures
The patients will have the following parameters and vital signs continuously monitored using wireless equipment:
Continuous glucose monitoring, Heart rate, Heart rhythm, Respiration rate, Peripheral oxygen saturation, Perfusion index and Blood pressure.
The monitoring period starts on the day of surgery or the day before and continues until the patient is discharged or for up to 10 days for continuous glucose monitoring and up to 5 days for the remaining modalities.
Primary outcome
Duration of glucose levels < 3.9 mmol/L as measured by continuous glucose monitoring (CGM)
Primary Investigator
Christian Jakob Carlsson, MD, PhD
NCT link
NCT04473001